Search PubMed⌕ Search

Biomedical subjects

M Hartikainen

Publications and source records attributed to M Hartikainen.

12 recordsLinked to original sources
PubMed1995

Prosthetic possibilities using endosseal implants as anchorages--an epidemiological study in 65-year-old subjects.

In order to evaluate the possibility of using endosseal implants (ITI Dental Implant System) and implant-retained prostheses for 65-year-old patients from a medium-sized Finnish city, 431 such patients were examined by means of panoramic radiographs. The population represents 61% of the total age group in the city (born in 1923). The possibility to construct a prosthesis, anchored on implants, was evaluated in three different groups. It was shown that in group I (edentulous maxilla and mandible, 256 patients) all male and 97% of female subjects could have been treated with implant-retained over-dentures in the lower jaw. Corresponding figures in the upper jaw were 62% for males and 59% for females. In patients with edentulous maxilla and dentulous or partially edentulous mandible (group II, 84 subjects) implant-retained overdenture in the maxilla could have been possible in 52% of male and 43% of female participants. In subjects with own teeth left in both jaws (group III, 91 participants) some kind of implant-retained bridge or single implants could have been constructed in 70% in maxilla and in 92% in mandible.

Aged↗
PubMed1995

General and local contraindications for endosseal implants--an epidemiological panoramic radiograph study in 65-year-old subjects.

In order to evaluate general and local contraindications for implantation for 65-yr-old subjects from a medium-sized Finnish city, 431 such persons were examined anamnestically and by means of panoramic radiographs. The population represents 61% of the total age group in the city (born in 1923). It was shown that several degrees of cardiac problems and increased blood pressure followed by pulmonary diseases and diabetes were the most commonly encountered relative contraindications for implantation. Eleven percent of the patients said that they smoked regularly and the bone quality was estimated to be less suitable for implantation in 21% of the cases. Implantation was evaluated according to the Bonefit system (implant lengths between 6 and 16 mm) in 10 regions in the maxilla and 6 regions in the mandible and was shown to be possible in 38% of the regions in the partially edentulous maxillae and 50% of those in the partially edentulous mandibles, the corresponding figures for the edentulous jaws were 55% in the maxilla and 61% in the mandible.

Aged↗
PubMed1992

Efficacy and tolerability of isradipine and metoprolol in treatment of hypertension: the Finnish Isradipine Study in Hypertension (FISH).

Eight hundred seventy-six men and women with diastolic blood pressure (DBP) of 95-115 mm Hg during a 4-week placebo period were included in a multicenter trial; 479 patients had previously been treated for hypertension. The patients were randomized to receive isradipine or metoprolol; both groups were comparable for age, weight, height, smoking habits, and duration of hypertension. By the end of the placebo period, 79 patients did not fulfill the final entry criteria and were withdrawn. The isradipine group consisted of 398 patients (164 women and 234 men), and the metoprolol group consisted of 399 patients (173 women and 226 men). The initial dose of isradipine was 1.25 mg twice daily (b.i.d.), and the initial dose of metoprolol was 50 mg b.i.d.; the doses were doubled after 4 weeks if DBP had not decreased to less than or equal to 90 mm Hg. After 8 weeks, the isradipine group began combination therapy with metoprolol 50 mg b.i.d. and the metoprolol group began combination therapy with isradipine 1.25 mg b.i.d. if DBP was not less than or equal to 90 mm Hg. After 8 weeks monotherapy, mean BP (MBP) was reduced by 13/11 mm Hg (161/104 to 148/93) in the isradipine group and by 15/12 mm Hg (160/103 to 145/91) in the metoprolol group. Monotherapy with isradipine normalized DBP to less than or equal to 90 mm Hg in 52% with a mean dose of 4.26 mg daily, and monotherapy with metoprolol normalized DBP in 58% with a mean dose of 155 mg daily.1+

Adult↗
PubMed1986

A double-blind comparison of indoramin and pindolol added to hydrochlorothiazide for the treatment of mild to moderate hypertension.

Sixty patients with mild to moderate essential hypertension, uncontrolled with diuretics alone, were evaluated in a double-blind randomized study that compared the effect of indoramin plus hydrochlorothiazide with that of pindolol plus hydrochlorothiazide. Following a 2-week period during which the patients were treated with 50 mg/day of hydrochlorothiazide, the patients were treated either with indoramin, 50-100 mg/day (n = 29), or with pindolol 10-20 mg/day (n = 30), in addition to the diuretic for 12 weeks. Systolic and diastolic blood pressures were significantly reduced after 2 weeks of treatment with indoramin or pindolol; blood pressure reduction was maintained for the 12 weeks of treatment. There were no significant differences between the indoramin and pindolol groups with respect to the changes in blood pressure. Blood pressure was controlled (less than or equal to 90 mm Hg) in 70% of the indoramin-treated patients and in 80% of the pindolol-treated patients. The difference was not significant. Heart rate was reduced after pindolol but not after indoramin. Side effects occurred in 20 patients (67%) treated with indoramin and in 14 patients (47%) treated with pindolol; the difference between the groups was not significant. Eight patients in the indoramin group and 10 patients in the pindolol group withdrew before completion of the study. In the indoramin group, four patients withdrew because of side effects and four because of lack of efficacy. In the pindolol group, five patients withdrew because of side effects and three because of lack of efficacy.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1982

Resurrection.

Explore the source record for details and available documents.

Humans↗
PubMed1978

Penbutolol, a new non-selective beta-adrenergic blocking compound in the treatment of hypertension. A comparision with propranolol.

The antihypertensive effect of a new non-selective beta-adrenergic blocking compound, penbutolol (40 mg b.i.d.), was compared with propranolol (160 mg b.i.d.) in a series of 20 hypertensive patients using a double-blind cross-over scheme. Both compounds reduced both the supine and the standing blood pressure significantly. The magnitude of the responses did not differ significantly and both compounds evoked a commensurate decrease in heart rate. No significant side-effects were noted and a series of laboratory tests did not disclose any biochemical changes.

Adrenergic beta-Antagonists↗
PubMed1976

Mitral valve replacement with ball and tilting disc valve prosthesis. A clinical and haemodynamic study.

A survey is presented on the results of 100 consecutive patients who underwent mitral valve (78 patients) or mitral and aortic and/or tricuspid valve replacement (22 patients) with ball or disc valve prosthesis. The patients were followed-up from 6 to 54 months postoperatively. The mortality for mitral valve replacement was 13 (17%) early deaths (up to one month from operation) and 5 (6%) late deaths. The corresponding figures for multiple valve replacements were 9 (41%) and 3 (14%). A direct correlation was found between early mortality and preoperative functional class IV of the New York Heart Association (30% dead). Pulmonary hypertension combined with multiple valve disease resulted in an early mortality of 42%. No significant differences in early mortality figures after MVR were found between ball and disc valve prostheses. Predominant complications were respiratory infection and atelectasis (13%), acute myocardial infarction (11%) and haemorrhage (9%). Haemolysis was found in 9 patients and three other patients had haemolytic anaemia attributable to paravalvular leak which in two indicated the reapplication of the prosthesis. The main causes of death were heart failure, 8 early and 4 late deaths, and myocardial infarction, 5 and 4 respectively.

Adolescent↗
PubMed1976

Comparison of verapamil and practolol in paroxysmal supraventricular tachycardia.

40 patients with paroxysmal supraventricular tachycardia were allocated to two different treatment groups according to their year of birth. Those patients born on odd years were given 5 mg of practolol intravenously, those born on even years receiving 5 mg of verapamil, and if the tachycardia continued, the same injection was repeated after 5 minutes. If practolol treatment failed, the patient was given 5 mg of verapamil half an hour later, and vice versa. Verapamil restored sinus rhythm in 19 patients out of 20. Practolol proved effective in 8 out of 20. In patients who were switched over to the other treatment verapamil was effective in 9 out of 11 and practolol in 1 patient. Side effects were few. Marked hypotension occurred in 2 patients, in 1 patient after 5 mg of verapamil, and after 5 mg of practolol in the other. It is concluded that verapamil is a very effective agent in the treatment of paroxysmal supraventricular tachycardia. Selection of patients is emphasized to increase the safety of its use.

Adolescent↗
PubMed1976

Twice-daily pindolol and alprenolol in essential hypertension of moderate severity.

A double-blind cross-over comparison of the antihypertensive actions of alprenolol and pindolol in equipotent doses was carried out in 22 patients with moderately severe essential hypertension. No other drugs were allowed. Ten patients were in WHO grade I, and 12 in grade II. The average initial pressures, similar after both the first and second 4-week placebo periods, were 175/116 mm Hg standing and 175/109 mm Hg supine. These pressures were decreased significantly by each beta-blocking drug, and about equally in both positions. An average reduction, using both 2-month treatment periods, was -13/-7 mm Hg with alprenolol, and with pindolol it was -23/-13 mm Hg. Both systolic and diastolic normotension (less than 160/100) in the supine position occurred in 45% of the patients when treated with alprenolol and in 64% with pindolol. With diastolic normotension alone the figures were 59% and 82% respectively. Rather low daily doses of 400 mg alprenolol and 20 mg pindolol were effective; increasing the doses to the average final levels of 533 mg alprenolol and 25 mg pindolol resulted in just negligible further pressure reductions. There were no serious side effects or complete resistance. Pindolol reduced the resting heart rate significantly in spite of its intrinsic sympathomimetic activity. Two aspects emerging from this study have clear practical implications. The twice-daily dosage, used here purposefully, of both alprenolol and of pindolol reduces effectively blood pressure, and increases patient convenience. Heat failure was not induced even in those 12 patients with cardiac involvement, including 5 with clear-cut radiological left ventricular enlargement.

Administration, Oral↗
PubMed1975

T-wave alternans associated with heart failure and hypomagnesemia in alcoholic cardiomyopathy.

Marked T wave abnormality developed in a patient with alcoholic cardiomyopathy. The T negativity was of giant size and occurred in an alternating sequence in the presence of sinus rhythm. This change was rapidly transient, disappearing in 3 days. The complete electrocardiographic recovery was temporally related to successful treatment of severe heart failure, normalization of initially low serum magnesium level, and abolition of recurrent ventricular fibrillation.

Alcoholism↗